---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-035194"
form_type: "8-K"
ticker: "ZLAB"
cik: "0001704292"
company_name: "Zai Lab Ltd"
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:20:16.537130+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zai Lab Q2 net product revenue $100.1M (+45% YoY); narrows net loss to $80.3M

## Summary
- Net product revenue $100.1M, up 45% YoY (47% at CER); VYVGART contributed $23.2M vs $0.1M YoY.
- Net loss $80.3M ($0.82/ADS loss), improved from $120.9M loss ($1.25/ADS) in Q2 2023.
- Raises full-year VYVGART revenue guidance to exceed $80.0M; cash position $730.0M as of June 30.
- Three NMPA product approvals: XACDURO (HABP/VABP), efgartigimod SC (gMG), AUGTYRO (ROS1+ NSCLC).
- Expanded global oncology pipeline with next-gen ROR1 ADC (ZL-6301) via MabCare partnership.

## SEC filing metadata
- accession: 0001628280-24-035194
- form_type: 8-K
- ticker: ZLAB
- cik: 0001704292
- company_name: Zai Lab Ltd
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704292/000162828024035194/0001628280-24-035194-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704292/000162828024035194/zlab-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-035194
- JSON: https://secwatch.observer/filing/0001628280-24-035194.json
- Plain text: https://secwatch.observer/filing/0001628280-24-035194.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.